BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

Core Insights - BioNxt Solutions Inc. has signed a non-binding letter of intent (LOI) for exclusive negotiations regarding the commercialization of its sublingual cladribine oral thin film (ODF) product in the Eurasian Patent Organization (EAPO) member states following recent patent grants in Eurasia and Europe [1][2][4] Patent Protection and Commercialization Strategy - The LOI outlines a structured pathway for a potential regional licensing arrangement, enhancing BioNxt's global intellectual property position [2][3] - BioNxt has secured patent protection for its cladribine ODF formulation from both the EAPO and the European Patent Office (EPO), valid through at least June 14, 2043 [6][8] - The EAPO patent covers sublingual delivery of therapeutic compounds, providing protection in eight member states with a combined population exceeding 200 million [7][9] Market Opportunity - The Eurasian region's population offers significant demographic reach for the commercialization of innovative therapies, while the European patent is expected to cover up to 39 jurisdictions, enhancing market access [9][10] - The global needle-free drug delivery market was valued at approximately USD 14.39 billion in 2024 and is projected to reach approximately USD 30.73 billion by 2032, indicating a growing demand for patient-centric drug delivery solutions [13][14] Development Pathway - BioNxt's development focus is on demonstrating bioequivalence of its sublingual formulation compared to existing tablet products, with preparations for a human bioequivalence study underway [15][16] - The company aims to leverage its differentiated, IP-protected delivery system to reduce development risk and enable an accelerated commercialization strategy [14][16]